Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.310
-0.040 (-2.96%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Alzamend Neuro Employees
As of April 30, 2026, Alzamend Neuro had 6 total employees, including 4 full-time and 2 part-time employees. The number of employees decreased by 1 or -14.29% compared to the previous year.
Employees
6
Change
-1
Growth
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,462,064
Market Cap
6.28M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Apr 30, 2026 | 6 | -1 | -14.29% | 4 | 2 |
| Jan 31, 2026 | 6 | -1 | -14.29% | 4 | 2 |
| Oct 31, 2025 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2025 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2025 | 7 | 0 | - | 4 | 3 |
| Jan 31, 2025 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2024 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2024 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2024 | 7 | 0 | - | 4 | 3 |
| Jan 31, 2024 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2023 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Apr 30, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Jan 31, 2023 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2022 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Apr 30, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Jan 31, 2022 | 7 | 3 | 75.00% | 3 | 4 |
| Oct 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Imunon | 20 |
| Processa Pharmaceuticals | 12 |
| Purple Biotech | 10 |
| XTL Biopharmaceuticals | 5 |
| Acurx Pharmaceuticals | 4 |
| Kairos Pharma | 4 |
| Addex Therapeutics | 3 |
| Pulmatrix | 2 |
ALZN News
- 12 days ago - Alzamend Neuro Annual report: Q4 2026 - Filings
- 13 days ago - Alzamend Neuro Slides: Corporate presentation - Filings
- 4 months ago - Alzamend Neuro’s AL001 shows “encouraging” data in Phase II brain trial - TheFly
- 4 months ago - Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital - PRNewsWire
- 4 months ago - Alzamend Neuro reports ‘positive’ data from Phase II clinical trial of AL001 - TheFly
- 4 months ago - Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions - PRNewsWire
- 4 months ago - Alzamend Neuro Slides: Corporate presentation - Filings
- 5 months ago - Alzamend Neuro initiates Phase II trial of AL001 study - TheFly